Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Date:1/22/2008

patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company will experience delays or difficulties in enrolling patients in the study and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in devel
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... the Phase III ZODIAC study in advanced non-small cell ... presented today at the American Society of Clinical Oncology ... met its primary endpoint, demonstrating that the addition of ... in progression-free survival (PFS), the length of time a ...
... at 45th American Society of Clinical Oncology Annual ... today announced results from Phase I and II ... inhibitor currently being studied in multiple tumor types. ... Annual Meeting of the American Society of Clinical ...
Cached Medicine Technology:Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 2Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 3Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 4Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology 5Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506 2Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506 3
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal ... that honor by the National Retail Federation, the largest retail trade association in the ... three Maine business owners to be named as such. According to the NRF’s website, ...
(Date:8/1/2015)... ... 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair ... first small business donation to kick off the campaign for healing and Well-Being. , ... includes a complete line of raw, organic hair care products, as well as her ...
(Date:7/31/2015)... ... , ... When the weather turned hot and warm-season turfgrasses, such as zoysia ... Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) for short. Incidentally, both names are ... type of sod, Super-Sod is giving away red Adirondack chairs with the Leisure Time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by Becker’s ... predictive health analytics , Jvion continues to disrupt the predictive analytic and big ... targets patient and population level illness to drive prevention and better health outcomes. ...
(Date:7/31/2015)... ... 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, Lakeview ... The medical community, social workers, law enforcement, and government officials are all invited ... effort to better understand and combat sex trafficking. Lead by sex trafficking expert ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... a Patient-Centered Medical Home Popular with Patients and ... of Ontario,s Family Health Team Model, which serves ... largest example of a patient-centered medical home. Implemented ... based on multidisciplinary teams and an innovative incentive-based ...
... MONDAY, March 14 (HealthDay News) -- Stroke survivors, even ... be independent if they are depressed, older, or have other ... stroke survivors, average age 62, who had no severe language ... with depression one month after their stroke. The patients, ...
... HealthDay Reporter , MONDAY, March 14 (HealthDay News) ... and use physical punishment, even on tots who are still ... 1-year-olds found they were more likely to spank and less ... The finding adds more weight to the emerging awareness of ...
... By Alan Mozes HealthDay Reporter , MONDAY, ... -- and the abundance of omega-3 fatty acids found in ... age-related macular degeneration (AMD), new research suggests. This latest ... health mirrors past research that has found the same benefit. ...
... Goodwin HealthDay Reporter , MONDAY, March 14 (HealthDay News) ... pediatrician or nurse they see regularly who offers comprehensive care -- ... new research finds. Yet it,s the sickest children -- those ... most care -- who are less likely to get the sort ...
... In a research study appearing in the journal Cancer ... Laboratory (CSHL) and four other institutions have identified a strategy ... limited treatment options and one of the worst one-year survival ... up to 15% of liver tumors are "driven" by the ...
Cached Medicine News:Health News:March/April 2011 Annals of Family Medicine tip sheet 2Health News:March/April 2011 Annals of Family Medicine tip sheet 3Health News:March/April 2011 Annals of Family Medicine tip sheet 4Health News:March/April 2011 Annals of Family Medicine tip sheet 5Health News:March/April 2011 Annals of Family Medicine tip sheet 6Health News:March/April 2011 Annals of Family Medicine tip sheet 7Health News:March/April 2011 Annals of Family Medicine tip sheet 8Health News:Depression Threatens Independence of Stroke Survivors 2Health News:Depressed Dads More Likely to Spank, Shortchange Kids: Study 2Health News:Depressed Dads More Likely to Spank, Shortchange Kids: Study 3Health News:Eating Fish Might Protect Your Eyesight 2Health News:Eating Fish Might Protect Your Eyesight 3Health News:'Medical Homes' Help Kids Get Comprehensive Care 2Health News:'Medical Homes' Help Kids Get Comprehensive Care 3Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 2Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 3
... been designed as a compact, cost-effective and ... private clinics or as a second system. ... most commonly required investigations such as Uroflowmetry, ... Add-on options are available for Urethral Pressure ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... Aquarius TT™ offers the ultimate research ... the most knowledgeable clinician and researcher today. ... a system to meet your desired footprint ... panels to display live data both in ...
... Advanced diagnostic capabilities combined with ease of ... product in its class. Ideal for office ... complete system for Uroflowmetry, cystometry, leak point ... configurations are available which make the OM-5 ...
Medicine Products: